Which TB test works best for HIV patients? new study aims to find out
NCT ID NCT04926922
First seen Jun 25, 2026 · Last updated Sep 02, 2026 · Updated 9 times
Summary
This study looked at 200 people living with HIV in Liberia to compare two tests for latent tuberculosis (TB) infection: a blood test (IGRA) and a skin test (TST). The goal was to see which test works better in this population. Participants had a skin test and their results were checked after 2-3 days. Those with a positive result got a chest X-ray and were referred for care if needed. The study is complete and aims to improve TB screening in Liberia.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- What this could lead to
- If successful, this could help identify the best screening method for latent TB in people with HIV, leading to better prevention and care in Liberia.
- What could go wrong
- This is an observational study comparing existing tests, not testing a new treatment. Results may not apply to other populations or settings.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
200 people
The number who actually took part.
- Started
-
Jul 2021
- Finished
-
Apr 2026
- Lead sponsor
-
A government research agency
The lead sponsor is the US National Institutes of Health.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
Adult participants must be enrolled in the main HONOR study of people living with HIV in Liberia who participated in the HONOR TB study at their Month 12 visit and tested positive on IGRA and/or TST.
- Ages
-
18 to 99 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
* INCLUSION CRITERIA: In order to be eligible to participate in this study, an individual must meet all of the following criteria: * Be a participant on the PREVAIL VIII/HONOR study. * Be at least 18 years of age. * Be scheduled to undergo or have undergone IGRA at a Month 12 HONOR study visit. * Ability to return to the clinic 48 to 72 hours after TST placement for reading. * Ability to provide informed consent. In order to be eligible to participate in the extension phase of the study, an individual must meet all of the following criteria: * Participated in the PREVAIL VIIIa HONOR TB study. * Have had a positive TB test result on the TST and/or IGRA performed as part of the PREVAIL VIII HONOR or PREVAIL VIIIa HONOR TB study(ies). * Ability to provide informed consent. EXCLUSION CRITERIA: An individual who meets any of the following criteria will be excluded from participation in this study: * Received BCG vaccine \<=10 years prior. * Known hypersensitivity or allergy to any component of the PPD product. * Previous severe reaction (e.g., necrosis, blistering, ulcerations, or anaphylactic shock) to a TST. * Documented active TB or a clear history of treatment for latent infection or active disease. * Extensive burns or eczema or other skin conditions on the forearms that could affect placement and reading of the TST. * Pregnant or lactating women. * Any condition that, in the opinion of the investigator, would compromise the safety of the study participant or staff, or would prevent proper conduct of the study. An individual who meets any of the following criteria will be excluded from participation in the extension phase of this study: * Pregnant women. * Contraindication to CT scanning. * Any condition that, in the opinion of the investigator, would compromise the safety of the study participant or staff, or would prevent proper conduct of the study. Exclusion of Special Populations (Children, Adults Who Lack Capacity to Consent, and Pregnant Women) -We are able to obtain knowledge about TST performance in Liberia without exposing children, adults who lack capacity to consent, and pregnant women to the potential risk of reactions to the TST or exposure to radiation for research purposes.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HIV are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
C.H. Rennie Hospital
Kakata, Liberia
-
Duport Road Clinic
Monrovia, Liberia
-
JFK Medical Center
Monrovia, Liberia
-
National Institutes of Health Cinical Center
Bethesda, Maryland, 20892, United States
-
Redemption Hospital
Monrovia, Liberia
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can 'Queen Mothers' bring HIV testing to the doorstep?
- Can a Once-Daily HIV pill with food match Twice-Daily dosing during TB treatment?
- Scientists map HIV's hiding spots in early infection
- Can simple sputum and urine tests catch tuberculosis earlier?
- Can a common virus be turned into a TB vaccine? scientists test VIR-1778
- Can local clinics keep more people with HIV in care?